Small Pharma Inc.
Small Pharma is a neuroscience company focused on the development of short-acting psychedelics with psychotherapy for under-served mental health patients. Currently leading the world's first clinical trial for DMT assisted therapy in major depression.
OTCQB: DMTTF
IR Website: https://smallpharma.com/investor-relations/
Headquarters: Vancouver, British Columbia
Content provided by Small Pharma Inc. on 3-11-22.
TALK TO MANAGEMENT
The Small Pharma management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Small Pharma is a neuroscience company focused on the development of short-acting psychedelics with psychotherapy for under-served mental health patients. Currently leading the world's first clinical trial for DMT assisted therapy in major depression.
Investor Presentation
Recent News
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
Mar 10, 2022
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
Feb 22, 2022
Small Pharma Reports Fiscal Third Quarter 2021 Highlights
Jan 31, 2022
Management Overview
Peter Rounds
Chief Executive Officer & Founder
Peter is a qualified patent attorney in the UK and Europe with over 10 years’ experience in the pharmaceutical industry and has always had a passion for pharmaceutical innovation. He graduated from the University of Oxford in 2003 with a first class degree in Chemistry, following which he trained and qualified as a UK and European patent attorney specializing in pharmaceuticals.
In 2008, he joined Teva Pharmaceutical, a generic drug company, to work directly with pharmaceutical formulation teams but left in 2011 to return to private practice with AmLaw 100 firm Mintz Levin, where he advised start-up and mid-cap innovative pharma firms on IP and legal matters.
Peter left Mintz Levin in 2015 to set up Small Pharma.
Dr. Carol Routledge
Chief Medical and Scientific Officer
Dr. Routledge is a dynamic R&D professional and drug development expert with over 30 years’ of experience across UK and US based pharmaceutical and biotechnology companies and the non-profit sector with a focus on drug acquisition and profiling of NCEs and biologics. She has also held multiple leadership roles across drug discovery and development.
Her preclinical and clinical experience spans psychiatric and neurological indications, with a strong focus on understanding and treating mental health disorders. Roles in Syntex, Wyeth, BTG and GlaxoSmithKline include leading drug discovery and development activities across several therapeutic areas with a strong focus on neuroscience diseases and an emphasis on translational medicine.
Dr. Routledge also has experience managing and sourcing opportunities at a semi-philanthropic dementia discovery fund. Other recent expertise includes leading the preclinical and clinical research strategy across Alzheimer’s Research UK for response-mode, strategic funding and for global projects and building and leading, as Managing Director, an independent and global initiative focused on the early detection of neurodegenerative diseases (EDoN).
She joined Small Pharma as CMSO mid-2020 and is responsible for oversight of all clinical, preclinical and associated regulatory functions.
She holds a 1st Class Honors degree in Zoology and a PhD in neuropharmacology.
George Tziras
Chief Business Officer
George has over 15 years of experience in investment banking and international capital markets having worked at a number of global financial institutions including Goldman Sachs, Credit Suisse, Nomura, Lehman Brothers and CIBC.
His experience spans a broad range of transactions including debt and equity financings; mergers, disposals and acquisitions; private equity buyouts and debt restructurings. He has also worked across a number of industries, including healthcare.
Holding a BA from the University of Oxford and a MA from the Johns Hopkins School of Advanced International Studies, he has been a director of Small Pharma since 2015.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Small Pharma Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
